Dual-Ligand Liposomes Nano carrier with Cisplatin and Anti-PD-L1 siRNA in Head and Neck Squamous Cell Carcinoma: A Review
نویسندگان
1 Bukhara State Medical Institute Named After Abu Ali Ibn Sino, Bukhara, Uzbekistan
2 Ferghana Medical Institute of Public Health, Republic of Uzbekistan
3 Tashkent State Technical University, Tashkent, Uzbekistan
4 Tashkent Medical Academy, Uzbekistan
5 Mamun University, Uzbekistan
6 Samarkand State Architecture and Construction University named after Mirzo Ulugbek, Uzbekistan
7 Bukhara State Medical Institute Named After Abu Ali Ibn Sino, Bukhara, Uzbekistan
8 Samarkand State Medical University, Samarkand, Uzbekistan
9 Tashkent Pharmaceutical Institute, Tashkent, Uzbekistan
10 Nukus branch of the Samarkand State University of Veterinary Medicine, livestock and Biotechnologies. Uzbekistan
11 Termez University of Economics and Service, Termez, Uzbekistan
12 Jizzakh State Pedagogical University, Jizzakh, Uzbekistan
13 Urgench State University, Urgench, Uzbekistan
doi
10.22052/JNS.2025.01.028چکیده
Head and neck squamous cell carcinoma (HNSCC) remains a therapeutic challenge due to its aggressive nature, immunosuppressive tumor microenvironment, and resistance to conventional therapies. Immune checkpoint modulation, particularly targeting the PD-1/PD-L1 axis, has shown promise but is limited by systemic toxicity and insufficient tumor-specific delivery. Combining chemotherapy with immune checkpoint blockade offers a synergistic strategy to enhance antitumor efficacy while mitigating immune evasion. This review explores the novel use of dual-ligand liposomes for the co-delivery of cisplatin, a platinum-based chemotherapeutic agent, and anti-PD-L1 siRNA to simultaneously induce tumor cell death and reverse PD-L1-mediated immunosuppression. By integrating two targeting ligands, these nanocarriers improve tumor specificity, reduce off-target effects, and enhance drug accumulation in HNSCC tissues. Preclinical studies demonstrate that this approach potentiates cisplatin’s cytotoxic effects while silencing PD-L1 to activate cytotoxic T lymphocytes, fostering a durable antitumor immune response. The dual-ligand design addresses key limitations of single-ligand systems, offering a platform for precise, combinatorial therapy.
